Laura E. Niklason - 12 Jun 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: President, CEO and Director, Director
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Issuer symbol: HUMA
Transactions as of: 12 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2025, 16:31:44 UTC
Previous filing: 23 Jan 2025
Next filing: 20 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Niklason Laura E	President, CEO and Director, Director	2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM	/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact	16 Jun 2025	0001878075

Transactions Table

Type	Sym	Class	Shares After	Date	Ownership	Footnotes
holding	HUMA	Common Stock	243,851	12 Jun 2025	Direct
holding	HUMA	Common Stock	0	12 Jun 2025	By spouse	F1
holding	HUMA	Common Stock	2,241,045	12 Jun 2025	By Ayabudge LLC	F1
holding	HUMA	Common Stock	1,148,240	12 Jun 2025	By The Niklason Living Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HUMA	Stock Options (right to buy)	Award	$0	0		$0.000000	0	12 Jun 2025	Common Stock	80,000	$2.41	By spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 4 amends the previously reported number of shares owned by Brady W. Dougan and Ayabudge LLC, an entity controlled by Brady W. Dougan, to correct an error in a Form 4 filed by the Reporting Person on August 21, 2023 (the "Original Form 4"). The Original Form 4 reported the sale of 510,161 shares of common stock of Humacyte, Inc. as a sale by Ayabudge LLC; however, these shares were sold by Mr. Dougan.
F2	The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.

Content

This Form 4 amends the previously reported number of shares owned by Brady W. Dougan and Ayabudge LLC, an entity controlled by Brady W. Dougan, to correct an error in a Form 4 filed by the Reporting Person on August 21, 2023 (the "Original Form 4"). The Original Form 4 reported the sale of 510,161 shares of common stock of Humacyte, Inc. as a sale by Ayabudge LLC; however, these shares were sold by Mr. Dougan.

The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.